Half-year report · HY
7459.TEDINET S100X3SK
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.90T | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥3.67T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.82T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥25.1bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥27.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥34.3bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥65.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥35.1bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥39.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥39.8bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥22.1bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥40.3bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥21.7bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥27.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥27.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.91T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.82T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.88T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.14T | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥1.07T | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥766.1bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥757.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥757.7bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥276.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥261.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥274.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥259.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥249.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥228.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.5bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥60.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥5.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥16.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥25.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥14.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥106.8 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥193.2 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥103.94 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.7% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.9% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | ¥160m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥625.1bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥625.0bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥139m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥13.9bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.22T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.21T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥1.8bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥9.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥1.90T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥1.90T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥24.9bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥161m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥58.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥600.4bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥600.2bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥201m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.0bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.17T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.17T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.83T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.82T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥27.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 512
| Item | Context | Value | Unit |
|---|---|---|---|
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 3000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | 20931000000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | 14825000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 228084000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 259337000000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 249016000000 | JPY |
| Cash and cash equivalents | InterimInstant | 274163000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1165840000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 600226000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 58606000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1824672000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 1824672000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1795000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 201000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1998000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -1998000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1167635000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 600427000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 58607000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1826671000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -1998000000 | JPY |
| Net sales | Prior1InterimDuration | 1824672000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 11854000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 13977000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1168000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 27001000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | 161000000 | JPY |
| Operating income | Prior1InterimDuration | 27162000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1213953000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 624996000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 58612000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1897562000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 1897562000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1846000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 139000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1987000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -1987000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 1215799000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 625135000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 58613000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 1899549000000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -1987000000 | JPY |
| Net sales | InterimDuration | 1897562000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 9673000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |